|
Found 32 result(s) FROM 1963 pages containing the term 'autoimmunity'.
Wednesday Mar 11, 2009
Biomarkers Are Red Flag for Rheumatoid Arthritis Risk
A soluble TNF receptor begins to increase many years before RA becomes clinically symptomatic and might make a useful screening tool to identify those at risk...
Friday Oct 10, 2008
Understanding RA Relapse After Pregnancy
New research sheds light on why rheumatoid arthritis (RA) tends to become reactivated in the postpartum period...
Thursday Mar 20, 2008
Merrimack Pharmaceuticals Completes Enrollment in a Phase II Study of MM-093, Recombinant AFP, in Patients With RA
Merrimack Pharmaceuticals, Inc's phase II trial to evaluate the safety and efficacy of MM-093, a nonglycosylated, recombinant version of human alpha-fetoprotein (AFP) in patients suffering from rheumatoid arthritis (RA) has completed enrollment...
Wednesday Oct 31, 2007
Coley Initiates Phase I Study of First-in-Class TLR Antagonist, CPG 52364, for the Treatment of Systemic Lupus Erythematosus
Coley Pharmaceutical Group, Inc, an international biopharmaceutical company having a pipeline of Toll-Like Receptor (TLR) therapeutic product candidates, announced that it has dosed its first subject in a phase I study of its novel, orally-available TLR Therapeutic drug candidate for the treatment of systemic lupus erythematosus (SLE)...
Wednesday Oct 03, 2007
First Case Reported of Lupus Erythematosus Tumidus Induced by Sex Reassignment Surgery
Environmental triggers contribute to lupus pathogenesis, and the hormone regimens used in male-to-female sex reassignment can induce lupus-like symptoms...
Tuesday May 22, 2007
Not Just Dust: Microparticles Suspected of Role in Lupus
Microparticles released from plasma membranes may be key to some of the autoimmune disturbances found in SLE patients...
Friday May 11, 2007
Lupus Gene Protects Against Malaria, But Does Malaria Also Prevent Lupus?
A mutation that renders the FcγRIIb receptor nonfunctional vastly improves monocytes' ability to clear malaria parasites, protects lupus-prone mice against malarial disease, and may explain the high prevalence of lupus in some population groups. Interestingly, there is also some evidence suggesting that the body's response to malarial infection might reduce lupus severity in some situations...Clatworthy MR, et al. Proc Natl Acad Sci USA. 2007;104:7169-7174.
Wednesday Feb 21, 2007
XDx Partners with the University of Minnesota and the Feinstein Institute to Develop Molecular Diagnostics to Improve the Clinical Management of Lupus
XDx Inc, a molecular diagnostics company that focuses on immune-mediated diseases, announced the signing of an agreement with the University of Minnesota to exclusively license key intellectual property assets in the field of systemic lupus erythematosus (SLE).
Tuesday Feb 13, 2007
Rheumatologists Advised to Be Alert for Signs of Serum Sickness in Rituximab-Treated Patients
The first case of rituximab-induced serum sickness in a patient without an underlying autoimmune disorder suggests that this problem might be under-recognized in RA and SLE patients...
Thursday Jan 04, 2007
RA Emerges as Major Burden in Developing Countries
The average societal cost of RA cases in Thailand is estimated at over 40% of patients' average annual income...
Thursday Dec 07, 2006
High-Dose Immune Suppression With or Without Stem Cell Transplants For Systemic Sclerosis
Studies are evaluating stem cell transplantation as a potential treatment for autoimmune disease, however, researchers sharply disagree regarding myeloablative vs nonmyeloablative approaches and whether stem cells are really necessary...
Monday Nov 13, 2006
Biomarkers Might Be Modifiable Risk Factors for RA
Autoantibodies may lead to risk reduction strategies for preventing RA... Holers VM. Presented at ACR 2006 Meeting.
Tuesday Sep 05, 2006
Medarex and GenPat77 to Codevelop Humanized Therapeutic Antibodies Against Immune Modulatory Targets
Medarex, Inc. and GenPat77 Pharmacogenetics AG have entered into a collaborative agreement to develop fully human therapeutic antibody products...
Friday Aug 04, 2006
Do Oral Contraceptives Protect Against RA Development?
Use of oral contraceptives may protect against the development of rheumatoid arthritis (RA), while smoking may increase the risk of developing the autoimmune disorder ... Bhatia, SS, et al. Ann Rheum Dis. 2006 July 25; [Epub ahead of print].
Thursday Jul 06, 2006
Fetal DNA in Maternal Serum Linked to RA Improvement in Pregnancy
Pregnancy-related improvements in RA disease activity parallel the levels of fetal DNA in maternal serum, suggesting a possible vaccine strategy …Yan Z, et al. Arthritis Rheum. 2006;54:2069-2073.
Tuesday Jun 27, 2006
Keep Prescribing MTX, Using X-rays for RA, EULAR Told
Pre-symptomatic diagnosis and better drugs should make RA remission for all a possibility within 10 years...Smolen, J. Presented at: EULAR 2006, 21-24 June 2006, Amsterdam, The Netherlands.
Thursday May 11, 2006
"Fossil Virus" Footprints Found in RA
Human endogenous K10 retroviruses, the residue of infections from generations past, are significantly more active in rheumatoid arthritis patients than in osteoarthritis patients or normal controls and might contribute to the development of autoimmune disease... Ejtehadi HD, et al. Ann Rheum Dis. 2006;65:612-616.
Wednesday Feb 01, 2006
Stem Cell Transplantation Shows Promise in Treatment-Resistant Lupus
Autologous nonmyeloablative hematopoietic stem cell transplantation ameliorates disease activity, improves serologic markers, and stabilizes or reverses organ dysfunction in about half of patients with treatment-refractory systemic lupus erythematosus... Burt RK, et al. JAMA. 2006;295:527-535.
Wednesday Dec 14, 2005
Modified Type II Collagen Found to Act as Autoantigen in RA
New research reveals the ability of modified type II collagen to act as an autoantigen in the inflamed joints of patients with rheumatoid arthritis (RA), possibly contributing to the cycle of chronicity associated with the disease… Nissim A, et al. Arthritis Rheum. 2005;52:3685-3692.
Thursday Nov 17, 2005
Three Novel and Distinct Agents Show Promise in RA
Three promising new rheumatoid arthritis (RA) drugs—including an oral small-molecule inhibitor that targets a novel adenosine receptor (AR) and a new anti-tumor necrosis factor-alpha (TNF-α) agent—may soon augment the rheumatologist's ever-expanding armamentarium... Presented at: Annual Meeting of the American College of Rheumatology; November 12–17, 2005; San Diego, Calif.
Monday Oct 31, 2005
Meta-Analysis Points to the Need to Customize Treatment for Subtypes of Juvenile Idiopathic Arthritis
With the increased recognition that radiologic joint and cartilage damage occurs earlier in the course of juvenile idiopathic arthritis than originally thought, a recently released literature review underlines the importance of taking a customized approach to treatment of the disease. However, despite treatment advances, researchers argue that there is no evidence-based consensus on the optimal treatment regimen for several subtypes of JIA. Hashkes PJ, Laxer RM. JAMA. 2005;294:1671-1684.
Tuesday Oct 18, 2005
MedImmune Completes Acquisition of Cellective and Its CD19-Directed Monoclonal Antibody; Files IND with Medarex for Lupus
MedImmune, Inc, of Gaithersburg, Maryland, announced that it has completed its acquisition of Cellective Therapeutics, Inc...
Friday Oct 07, 2005
Novel Population of T Cells Found to Produce IL-17; In Vivo Analysis Reveals Role of Cytokine in Inflammatory Disease
New research examining the production and function of the inflammatory cytokine interleukin 17 (IL-17) may pave the way for more effective ways to prevent and treat rheumatoid arthritis (RA) and other autoimmune and inflammatory conditions . . . Nat Immunol [serial online]. October 2, 2005.
Friday Sep 16, 2005
Abatacept Beneficial to Patients with RA Refractory to TNF-α Inhibitors
Abatacept has shown benefit to rheumatoid arthritis patients with inadequate response to tumor necrosis factor (TNF)-α inhibitors, according to the results of a randomized, double-blind study...Genovese MC, et al. N Engl J Med. 2005;353:1114-1123.
Thursday Sep 08, 2005
Cyclophosphamide/Stem Cell Transplantation Protocol Shows Promise for Refractory Autoimmune Diseases
Japanese researchers report promising phase I-II trial results showing that high-dose cyclophosphamide supported by autologous peripheral blood stem cell transplantation is feasible and may be effective in the treatment of severe and refractory autoimmune diseases such as systemic sclerosis and SLE...Tsukamoto H, et al. Ann Rheum Dis online August 26, 2005
Monday Aug 29, 2005
Research Clarifies Mechanisms of Self-Tolerance by Natural Killer Cells
New murine research depicting how natural killer cells mature in a healthy immune system may yield clues as to what goes awry in autoimmune disorders. Kim S, et al. Nature. 2005;436:709-713
Friday Aug 19, 2005
Stem-Cell Transplantation Temporarily Improves Function and Health Status in RA Patients
New research helps delineate some of the benefits and potential limitations of high-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation in patients with severe refractory rheumatoid arthritis. Teng YK, et al. Arthritis Rheum. 2005;52:2272-2276.
Tuesday Jul 26, 2005
Systemic Lupus Erythematosus: Is There a Phthalate Connection?
Murine studies suggest that exposure to phthalates may increase susceptibility to SLE and possibly other autoimmune disorders... Lim S-Y and Ghosh SK. J Autoimmun. 2005;25:33-45
Tuesday Apr 26, 2005
American College of Rheumatology Responds to the Recent FDA Action on NSAIDs
Citing a lack of evidence implicating OTC and prescription NSAIDs in CV risk, the American College of Rheumatology criticized aspects of the recent FDA decision... American College of Rheumatology letter to Lester M. Crawford, DVM, PhD, acting commissioner of the FDA. April 21, 2005.
Friday Dec 10, 2004
Occupational Risk Factors for Systemic Lupus Erythematosus May Include Mercury Exposure and Pesticide Mixing
Epidemiologic study indicates that occupational mercury exposure and some dental and agricultural work are significantly associated with a greater risk for developing SLE and that previously suspected occupations may not present this risk...Cooper GS, et al. J Rheumatol. 2004;31:1928-1933.
Monday Oct 18, 2004
Key Contributors to Rheumatology Acknowledged in ACR 2004 Awards
The opening plenary session acknowledged the recipients of the Presidential Gold Medal, the Distinguished Investigator Award, and the Distinguished Rheumatologist Award.
Monday Aug 30, 2004
SLE Researchers Encouraged to Use Biomarkers, Surrogate Markers as Study Endpoints; New Research Shows B-Cell Depletion to Have Role in SLE Therapy
(Schiffenbauer J, et al. Arthritis Rheum. 2004;50:2415-2422; Looney RJ, et al. Arthritis Rheum. 2004;50:2580-2589.)
|
